Bex5 Activators
The Bex5 activators chemical class encompasses a diverse array of compounds that intricately modulate the activity of Bex5 through multifaceted signaling pathways. These chemicals exert their influence by engaging directly with Bex5 or by influencing pivotal regulatory pathways within the cellular milieu. ATRA, for instance, orchestrates the activation of Bex5 through the retinoic acid signaling pathway, where it forms a complex with RXR, delineating a precise mechanism for its impact. This indirect modulation facilitates the activation of Bex5, showcasing the nuanced interplay within cellular cascades. LY294002 disrupts PI3K/Akt signaling, providing another avenue for the relief of inhibition on Bex5. Forskolin and Rapamycin further contribute to the repertoire of Bex5 activators, steering cellular pathways through cAMP and mTOR mechanisms.
The intricate orchestration continues with Triciribine, which acts as a sentinel against Akt-mediated repression of Bex5.PD98059 and BIRB 796 join forces to indirectly activate Bex5 by disrupting MAPK pathways, revealing the interconnectedness of signaling networks. H89 plays a role in this symphony by inhibiting PKA, relieving its suppressive influence on Bex5. NSC23766 adds another layer of complexity, indirectly activating Bex5 by disrupting downstream signaling events. This rich diversity of chemicals stands as a compendium of invaluable tools for researchers, providing nuanced insights into the intricate landscape of Bex5 activity across diverse cellular contexts. These chemical modulators not only enhance our understanding of Bex5 but also offer the means to manipulate its activity with precision, contributing to the broader endeavor of unraveling the complexities of cellular signaling pathways.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
ATRA activates Bex5 through the retinoic acid signaling pathway. As a ligand for nuclear receptors, it forms a complex with RXR, influencing downstream targets. This interaction leads to the activation of Bex5, highlighting the role of ATRA in modulating Bex5 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a JNK inhibitor, indirectly activates Bex5. By inhibiting JNK, it disrupts the downstream signaling cascade, relieving its inhibitory effect on Bex5 activation, resulting in increased Bex5 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580, a p38 MAPK inhibitor, indirectly activates Bex5. Inhibition of p38 MAPK disrupts the downstream signaling pathway, relieving its negative influence on Bex5. This leads to increased Bex5 activation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a PI3K inhibitor, indirectly activates Bex5. By inhibiting PI3K, it disrupts the PI3K/Akt signaling pathway, relieving its inhibitory effect on Bex5 activation, ultimately leading to increased Bex5 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059, a MEK inhibitor, indirectly activates Bex5. By inhibiting MEK, it dampens the MAPK pathway, relieving its negative influence on Bex5 activation. This disruption leads to increased Bex5 activity. | ||||||
Doramapimod | 285983-48-4 | sc-300502 sc-300502A sc-300502B | 25 mg 50 mg 100 mg | $149.00 $281.00 $459.00 | 2 | |
BIRB 796, a p38 MAPK inhibitor, indirectly activates Bex5. Inhibition of p38 MAPK disrupts the downstream signaling pathway, relieving its inhibitory effect on Bex5 activation, resulting in increased Bex5 activity. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine, an Akt inhibitor, indirectly activates Bex5. Akt phosphorylates Bex5, negatively regulating its activity. Inhibition of Akt by Triciribine prevents this phosphorylation, leading to the indirect activation of Bex5. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin activates Bex5 through the mTOR pathway. It forms a complex with FKBP12, inhibiting mTOR and relieving its inhibitory effect on Bex5 activation. This interaction leads to increased Bex5 activity. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $71.00 $202.00 | 18 | |
SB216763, a GSK-3 inhibitor, indirectly activates Bex5. GSK-3 negatively regulates Bex5 through phosphorylation. Inhibition of GSK-3 by SB216763 prevents this phosphorylation, leading to increased Bex5 activation. | ||||||